Bausch Health Companies (BHC) Stock Forecast, Price Target & Predictions
BHC Stock Forecast
Bausch Health Companies stock forecast is as follows: an average price target of $10.00 (represents a 7.99% upside from BHC’s last price of $9.26) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
BHC Price Target
The average price target for Bausch Health Companies (BHC) is $10.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $16.00 to $7.00. This represents a potential 7.99% upside from BHC's last price of $9.26.
BHC Analyst Ratings
According to 5 Wall Street analysts, Bausch Health Companies's rating consensus is 'Hold'. The analyst rating breakdown for BHC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (20.00%), 3 'Hold' (60.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Bausch Health Companies Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | Douglas Miehm | RBC Capital | $10.00 | $8.06 | 23.99% | 7.99% |
| Jul 25, 2024 | Les Sulewski | Truist Financial | $7.00 | $5.69 | 23.06% | -24.41% |
| Jul 10, 2024 | Michael Freeman | Raymond James | $8.00 | $7.19 | 11.27% | -13.61% |
| Apr 29, 2024 | David Amsellem | Piper Sandler | $9.00 | $8.78 | 2.56% | -2.81% |
| Apr 23, 2024 | Doug Miehm | RBC Capital | $11.00 | $8.45 | 30.18% | 18.79% |
| Apr 11, 2024 | Glen Santangelo | Jefferies | $16.00 | $9.28 | 72.51% | 72.79% |
| Apr 05, 2024 | Doug Miehm | RBC Capital | $12.00 | $10.05 | 19.40% | 29.59% |
| Sep 09, 2022 | - | Piper Sandler | $6.00 | $6.70 | -10.45% | -35.21% |
| Jul 26, 2022 | - | RBC Capital | $12.00 | $8.73 | 37.38% | 29.59% |
| May 13, 2022 | - | RBC Capital | $17.00 | $10.45 | 62.68% | 83.59% |
The latest Bausch Health Companies stock forecast, released on Oct 23, 2024 by Douglas Miehm from RBC Capital, set a price target of $10.00, which represents a 23.99% increase from the stock price at the time of the forecast ($8.06), and a 7.99% increase from BHC last price ($9.26).
Bausch Health Companies Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 7 |
| Avg Price Target | $10.00 | $10.00 | $10.43 |
| Last Closing Price | $9.26 | $9.26 | $9.26 |
| Upside/Downside | 7.99% | 7.99% | 12.63% |
In the current month, the average price target of Bausch Health Companies stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 7.99% increase as opposed to Bausch Health Companies's last price of $9.26. This month's average price target is down 0.00% compared to last quarter, and down -4.12% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 01, 2024 | Piper Sandler | Neutral | Underweight | Downgrade |
| Jul 10, 2024 | Raymond James | - | Market Perform | Initialise |
| Apr 29, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 08, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Apr 05, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Mar 28, 2024 | Jefferies | Buy | Buy | Hold |
| Feb 23, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Sep 09, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| Jul 26, 2022 | RBC Capital | Outperform | Outperform | Hold |
Bausch Health Companies's last stock rating was published by RBC Capital on Oct 23, 2024. The company gave BHC a "Sector Perform" rating, the same as its previous rate.
Bausch Health Companies Financial Forecast
Bausch Health Companies Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $2.24B | $2.17B | $1.94B | $2.19B | $2.05B | $1.97B | $1.92B | $2.20B | $2.11B | $2.10B | $2.03B | $2.21B | $2.14B | $1.66B | $2.01B | $2.22B | $2.21B | $2.15B | $2.02B | $2.00B | $2.11B |
| Avg Forecast | $2.65B | $2.56B | $2.47B | $2.26B | $2.51B | $2.48B | $2.35B | $2.19B | $2.33B | $2.17B | $2.03B | $1.97B | $2.14B | $1.99B | $2.04B | $2.08B | $2.19B | $2.12B | $2.11B | $2.05B | $2.17B | $2.01B | $1.78B | $2.00B | $2.23B | $2.15B | $2.18B | $2.04B | $1.36B | $2.35B |
| High Forecast | $2.70B | $2.61B | $2.52B | $2.27B | $2.59B | $2.53B | $2.40B | $2.23B | $2.36B | $2.19B | $2.07B | $2.01B | $2.18B | $1.99B | $2.04B | $2.08B | $2.19B | $2.12B | $2.11B | $2.05B | $2.17B | $2.01B | $1.78B | $2.00B | $2.23B | $2.15B | $2.18B | $2.04B | $1.63B | $2.82B |
| Low Forecast | $2.61B | $2.52B | $2.44B | $2.25B | $2.48B | $2.44B | $2.31B | $2.16B | $2.30B | $2.15B | $2.00B | $1.94B | $2.11B | $1.99B | $2.04B | $2.08B | $2.19B | $2.12B | $2.11B | $2.05B | $2.17B | $2.01B | $1.78B | $2.00B | $2.23B | $2.15B | $2.18B | $2.04B | $1.09B | $1.88B |
| # Analysts | 3 | 3 | 3 | 5 | 6 | 3 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.07% | 0.99% | 1.03% | 1.03% | 0.96% | 0.92% | 1.00% | 1.00% | 0.99% | 0.99% | 1.02% | 1.06% | 0.94% | 1.01% | 1.00% | 1.03% | 0.99% | 0.99% | 1.47% | 0.90% |
Bausch Health Companies's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.33B, with a low forecast of $2.30B, and a high forecast of $2.36B. BHC's average Quarter revenue forecast represents a 4.27% increase compared to the company's last Quarter revenue of $2.24B (Sep 23).
Bausch Health Companies EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 6 | 3 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | $14.00M | $412.00M | $477.00M | $710.00M | $716.00M | $636.00M | $618.00M | $724.00M | $946.00M | $96.00M | $177.00M | $412.00M | $886.00M | $427.00M | $699.00M | $-586.00M | $859.00M | $760.00M | $812.00M | $-1.49B | $852.00M |
| Avg Forecast | $783.59M | $757.69M | $731.38M | $669.95M | $744.43M | $732.81M | $694.94M | $972.09M | $690.88M | $643.04M | $601.50M | $883.71M | $682.63M | $590.36M | $605.23M | $803.38M | $648.59M | $626.89M | $625.73M | $158.17M | $643.27M | $595.25M | $526.16M | $699.00M | $660.92M | $635.11M | $644.67M | $660.93M | $-876.48M | $940.14M |
| High Forecast | $799.80M | $773.37M | $746.51M | $672.92M | $768.16M | $747.97M | $709.31M | $1.17B | $700.10M | $647.52M | $613.94M | $1.06B | $819.15M | $590.36M | $605.23M | $964.05M | $648.59M | $626.89M | $625.73M | $189.80M | $643.27M | $595.25M | $526.16M | $838.80M | $660.92M | $635.11M | $644.67M | $793.12M | $-701.18M | $1.13B |
| Low Forecast | $772.69M | $747.15M | $721.20M | $666.99M | $735.53M | $722.62M | $685.27M | $777.67M | $681.67M | $637.22M | $593.13M | $706.97M | $546.10M | $590.36M | $605.23M | $642.70M | $648.59M | $626.89M | $625.73M | $126.54M | $643.27M | $595.25M | $526.16M | $559.20M | $660.92M | $635.11M | $644.67M | $528.74M | $-1.05B | $752.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.02% | 0.68% | 0.54% | 1.04% | 1.21% | 1.05% | 0.77% | 1.12% | 1.51% | 0.15% | 1.12% | 0.64% | 1.49% | 0.81% | 1.00% | -0.89% | 1.35% | 1.18% | 1.23% | 1.70% | 0.91% |
3 analysts predict BHC's average Quarter EBITDA for Dec 23 to be $690.88M, with a high of $700.10M and a low of $681.67M. This is 4834.88% upper than Bausch Health Companies's previous annual EBITDA (Sep 23) of $14.00M.
Bausch Health Companies Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 6 | 3 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | $-378.00M | $131.00M | $-209.00M | $-410.00M | $399.00M | $-139.00M | $-66.00M | $72.00M | $188.00M | $-595.00M | $-610.00M | $-153.00M | $71.00M | $-326.00M | $-152.00M | $-1.52B | $-49.00M | $-171.00M | $-52.00M | $-2.69B | $628.00M |
| Avg Forecast | $481.20M | $463.81M | $388.50M | $300.05M | $418.54M | $385.71M | $323.98M | $-106.64M | $382.62M | $341.34M | $260.67M | $-96.94M | $65.06M | $301.91M | $337.27M | $-88.13M | $410.40M | $380.75M | $355.81M | $-545.11M | $418.09M | $372.21M | $243.13M | $-152.00M | $432.97M | $400.41M | $394.87M | $-42.33M | $-1.58B | $692.97M |
| High Forecast | $494.14M | $476.28M | $398.94M | $331.82M | $495.64M | $386.00M | $325.43M | $-85.31M | $394.10M | $378.44M | $267.67M | $-77.55M | $78.07M | $301.91M | $337.27M | $-70.50M | $410.40M | $380.75M | $365.08M | $-436.09M | $418.09M | $372.21M | $243.13M | $-121.60M | $432.97M | $400.41M | $394.87M | $-33.86M | $-1.26B | $831.56M |
| Low Forecast | $472.50M | $455.42M | $381.47M | $282.40M | $330.43M | $385.42M | $322.53M | $-127.96M | $378.80M | $304.24M | $255.95M | $-116.33M | $52.05M | $301.91M | $337.27M | $-105.75M | $410.40M | $380.75M | $346.54M | $-654.13M | $418.09M | $372.21M | $243.13M | $-182.40M | $432.97M | $400.41M | $394.87M | $-50.79M | $-1.90B | $554.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.11% | 0.50% | 2.16% | -6.30% | 1.32% | -0.41% | 0.75% | 0.18% | 0.49% | -1.67% | 1.12% | -0.37% | 0.19% | -1.34% | 1.00% | -3.50% | -0.12% | -0.43% | 1.23% | 1.70% | 0.91% |
Bausch Health Companies's average Quarter net income forecast for Sep 23 is $341.34M, with a range of $304.24M to $378.44M. BHC's average Quarter net income forecast represents a 160.56% increase compared to the company's last Quarter net income of $131.00M (Jun 23).
Bausch Health Companies SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 6 | 3 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | $715.00M | $711.00M | $725.00M | $666.00M | $661.00M | $676.00M | $622.00M | $680.00M | $653.00M | $685.00M | $606.00M | $636.00M | $572.00M | $526.00M | $633.00M | $668.00M | $648.00M | $651.00M | $587.00M | $591.00M | $661.00M |
| Avg Forecast | $825.30M | $798.03M | $770.31M | $705.62M | $784.06M | $771.83M | $731.94M | $961.27M | $727.66M | $677.28M | $633.52M | $873.88M | $641.14M | $621.78M | $637.45M | $794.44M | $683.12M | $660.26M | $659.04M | $541.53M | $677.52M | $626.93M | $554.17M | $633.00M | $696.10M | $668.92M | $678.99M | $477.79M | $346.72M | $729.38M |
| High Forecast | $842.37M | $814.54M | $786.25M | $708.74M | $809.05M | $787.79M | $747.08M | $1.15B | $737.36M | $681.99M | $646.62M | $1.05B | $769.37M | $621.78M | $637.45M | $953.32M | $683.12M | $660.26M | $659.04M | $649.84M | $677.52M | $626.93M | $554.17M | $759.60M | $696.10M | $668.92M | $678.99M | $573.35M | $416.06M | $875.26M |
| Low Forecast | $813.82M | $786.93M | $759.60M | $702.50M | $774.69M | $761.09M | $721.75M | $769.01M | $717.96M | $671.14M | $624.71M | $699.10M | $512.91M | $621.78M | $637.45M | $635.55M | $683.12M | $660.26M | $659.04M | $433.23M | $677.52M | $626.93M | $554.17M | $506.40M | $696.10M | $668.92M | $678.99M | $382.23M | $277.38M | $583.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.06% | 1.12% | 0.83% | 1.04% | 1.06% | 1.06% | 0.78% | 1.00% | 0.99% | 1.04% | 1.12% | 0.94% | 0.91% | 0.95% | 1.00% | 0.96% | 0.97% | 0.96% | 1.23% | 1.70% | 0.91% |
Bausch Health Companies's average Quarter SG&A projection for Dec 23 is $727.66M, based on 3 Wall Street analysts, with a range of $717.96M to $737.36M. The forecast indicates a 1.77% rise compared to BHC last annual SG&A of $715.00M (Sep 23).
Bausch Health Companies EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 6 | 3 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.03 | $0.36 | $-0.58 | $-1.13 | $1.10 | $-0.38 | $-0.18 | $0.20 | $0.52 | $-1.66 | $-1.71 | $-0.43 | $0.20 | $-0.92 | $-0.43 | $-4.30 | $-0.14 | $-0.49 | $-0.15 | $-7.68 | $1.80 |
| Avg Forecast | $1.31 | $1.26 | $1.05 | $0.81 | $1.14 | $1.05 | $0.88 | $0.69 | $1.04 | $0.93 | $0.71 | $0.65 | $0.94 | $0.82 | $0.91 | $1.05 | $1.11 | $1.03 | $0.96 | $0.95 | $1.13 | $1.01 | $0.66 | $0.86 | $1.17 | $1.08 | $1.07 | $0.86 | $0.35 | $0.96 |
| High Forecast | $1.34 | $1.29 | $1.08 | $0.90 | $1.35 | $1.05 | $0.88 | $0.69 | $1.07 | $1.03 | $0.73 | $0.67 | $0.97 | $0.82 | $0.91 | $1.05 | $1.11 | $1.03 | $0.99 | $0.95 | $1.13 | $1.01 | $0.66 | $0.86 | $1.17 | $1.08 | $1.07 | $0.86 | $0.42 | $1.15 |
| Low Forecast | $1.28 | $1.24 | $1.04 | $0.77 | $0.90 | $1.05 | $0.88 | $0.68 | $1.03 | $0.83 | $0.69 | $0.64 | $0.93 | $0.82 | $0.91 | $1.05 | $1.11 | $1.03 | $0.94 | $0.95 | $1.13 | $1.01 | $0.66 | $0.86 | $1.17 | $1.08 | $1.07 | $0.86 | $0.28 | $0.77 |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.11% | 0.51% | -0.89% | -1.20% | 1.35% | -0.42% | -0.17% | 0.18% | 0.51% | -1.73% | -1.81% | -0.38% | 0.20% | -1.40% | -0.50% | -3.68% | -0.13% | -0.46% | -0.17% | -21.94% | 1.88% |
According to 5 Wall Street analysts, Bausch Health Companies's projected average Quarter EPS for Sep 23 is $0.93, with a low estimate of $0.83 and a high estimate of $1.03. This represents a 157.37% increase compared to BHC previous annual EPS of $0.36 (Jun 23).
Bausch Health Companies Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions | $8.77 | $51.50 | 487.23% | Buy |
| TLRY | Tilray Brands | $1.73 | $7.42 | 328.90% | Hold |
| CTLT | Catalent | $58.69 | $76.40 | 30.18% | Hold |
| ZTS | Zoetis | $175.18 | $227.71 | 29.99% | Buy |
| NBIX | Neurocrine Biosciences | $120.53 | $147.70 | 22.54% | Buy |
| VTRS | Viatris | $11.45 | $13.75 | 20.09% | Hold |
| LFCR | Lifecore Biomedical | $5.99 | $6.50 | 8.51% | Buy |
| BHC | Bausch Health Companies | $9.26 | $10.00 | 7.99% | Hold |
| TEVA | Teva Pharmaceutical Industries | $18.64 | $20.00 | 7.30% | Buy |
| PETQ | PetIQ | $30.98 | $31.00 | 0.06% | Buy |
| HLN | Haleon | $9.76 | $9.15 | -6.25% | Buy |
BHC Forecast FAQ
Is Bausch Health Companies a good buy?
No, according to 5 Wall Street analysts, Bausch Health Companies (BHC) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 20.00% of BHC's total ratings.
What is BHC's price target?
Bausch Health Companies (BHC) average price target is $10 with a range of $7 to $16, implying a 7.99% from its last price of $9.26. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bausch Health Companies stock go up soon?
According to Wall Street analysts' prediction for BHC stock, the company can go up by 7.99% (from the last price of $9.26 to the average price target of $10), up by 72.79% based on the highest stock price target, and down by -24.41% based on the lowest stock price target.
Can Bausch Health Companies stock reach $14?
BHC's highest twelve months analyst stock price target of $16 supports the claim that Bausch Health Companies can reach $14 in the near future.
What is Bausch Health Companies's current price target trend?
1 Wall Street analyst forecast a $10 price target for Bausch Health Companies (BHC) this month, up 7.99% from its last price of $9.26. Compared to the last 3 and 12 months, the average price target increased by 7.99% and increased by 12.63%, respectively.
What are Bausch Health Companies's analysts' financial forecasts?
Bausch Health Companies's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $9.52B (high $9.75B, low $9.4B), average EBITDA is $3.14B (high $3.39B, low $2.92B), average net income is $1.02B (high $1.12B, low $910.41M), average SG&A $3.25B (high $3.5B, low $3.03B), and average EPS is $3.75 (high $3.97, low $3.5). BHC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.94B (high $10.11B, low $9.82B), average EBITDA is $2.94B (high $2.99B, low $2.91B), average net income is $1.63B (high $1.7B, low $1.59B), average SG&A $3.1B (high $3.15B, low $3.06B), and average EPS is $4.43 (high $4.62, low $4.32).
Did the BHC's actual financial results beat the analysts' financial forecasts?
Based on Bausch Health Companies's last annual report (Dec 2022), the company's revenue was $8.12B, which missed the average analysts forecast of $8.25B by -1.58%. Apple's EBITDA was $2.58B, missing the average prediction of $2.68B by -3.60%. The company's net income was $-212M, missing the average estimation of $616.1M by -134.41%. Apple's SG&A was $2.62B, missing the average forecast of $2.69B by -2.59%. Lastly, the company's EPS was $-0.59, missing the average prediction of $3.72 by -115.86%. In terms of the last quarterly report (Sep 2023), Bausch Health Companies's revenue was $2.24B, beating the average analysts' forecast of $2.17B by 3.04%. The company's EBITDA was $14M, missing the average prediction of $643.04M by -97.82%. Bausch Health Companies's net income was $-378M, missing the average estimation of $341.34M by -210.74%. The company's SG&A was $715M, beating the average forecast of $677.28M by 5.57%. Lastly, the company's EPS was $-1.03, missing the average prediction of $0.927 by -211.17%